ArticleeNeurologicalSci2025
Effects of immunotherapy on isolated optic neuritis associated with ozoralizumab, a novel anti-tumor necrosis factor α NANOBODY® compound: A case report.
Article in eNeurologicalSci, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF)-α inhibitors rarely cause optic neuritis as a side effect although the disease associated with ozoralizumab, a novel anti-TNF-α NANOBODY® compound, has not been reported. A 76-year-old female with rheumatoid arthritis, medicated with ozoralizumab, was hospitalized with a two-day history of extending partial visual field loss in the left eye. Campimetry revealed top horizontal hemianopia in the left eye. Swelling and abnormally high intensity of the left optic nerve were observed in magnetic resonance imaging. Visual evoked potential tests revealed delayed latency and reduced amplitude on the left side. She was diagnosed with ozoralizumab-associated isolated optic neuritis and cured with two courses of high-dose intravenous methylprednisolone, followed by oral prednisolone. Ozoralizumab may be associated with optic neuritis although early diagnosis and immunotherapy possibly achieve a good outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.